---
title: "Depth and Durability of Response with Durvalumab–Tremelimumab vs Atezolizumab–Bevacizumab in Unres"
id: "pubmed-42674706"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42674706"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42674706/"
doi: "10.21873/anticanres.18366"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Depth and Durability of Response with Durvalumab–Tremelimumab vs Atezolizumab–Bevacizumab in Unres
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42674706
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42674706/)
- **DOI:** [10.21873/anticanres.18366](https://doi.org/10.21873%2Fanticanres.18366)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This retrospective, single-center analysis described **response dynamics** in 148 patients with unresectable hepatocellular carcinoma (HCC) treated with either **durvalumab plus tremelimumab** (n=53) or **atezolizumab plus bevacizumab** (n=95). - The study evaluated conventional endpoints and additional response features: depth of response (DpR), time to response, and duration of response. A ≥50% reduction in target lesion diameter was defined as **DpR50**. - Analysis was descriptive and hypothesis-generating because of baseline imbalances and different observation periods between groups; no formal hypothesis testing was reported. - Overall response rate (ORR) was 35.8% for durvalumab–tremelimumab and 27.4% for atezolizumab–bevacizumab; disease control rate (DCR) was 54.7% and 71.6%, respectively. - **DpR50** occurred in 26.4% of patients receiving durvalumab–tremelimumab versus 11.6% with atezolizumab–bevacizumab, indicating deeper shrinkage in a subset of durvalumab–tremelimumab responders. - Median time to response was shorter with durvalumab–tremelimumab (2.3 months) than with atezolizumab–bevacizumab (3.3 months). - Median duration of response was longer after durvalumab–tremelimumab (22.3 months) than after atezolizumab–bevacizumab (10.0 months); durable responses ≥6 months occurred in 24.5% versus 15.8% of all treated patients. - Median progression-free survival (PFS) was 5.2 months for durvalumab–tremelimumab and 7.0 months for atezolizumab–bevacizumab; median overall survival (OS) was 17.0 and 22.0 months, respectively. - Authors concluded that durvalumab–tremelimumab was associated with deeper and more durable tumor shrinkage in selected responders, while atezolizumab–bevacizumab produced broader disease control mainly via stable disease; findings are hypothesis-generating.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42674706/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674706%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42674706/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42674706/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42674706/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42674706/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42674706/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674706%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674706%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42674706/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674706/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674706/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42674706/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674706/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42674706/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42674706/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42674706/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42674706/#substances) Title & authors Abstract MeSH terms Substances Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) . 2026 Sep;46(9):5217-5227. doi: 10.21873/anticanres.18366. # Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma [Akifumi Kuwano](https://pubmed.ncbi.nlm.nih.gov/?term=Kuwano+A&cauthor_id=42674706)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-1 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com."), [Masayoshi Yada](https://pubmed.ncbi.nlm.nih.gov/?term=Yada+M&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-3 "Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan."), [Kosuke Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Taikan Hamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Hamamoto+T&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Ryotaro Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+R&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Kazuki Kurosaka](https://pubmed.ncbi.nlm.nih.gov/?term=Kurosaka+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Hideo Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+H&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Kenta Motomura](https://pubmed.ncbi.nlm.nih.gov/?term=Motomura+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#full-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.") Affiliations Expand ### Affiliations * 1 Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. * 2 Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan. * 3 Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan. * PMID: **42674706** * DOI: [ 10.21873/anticanres.18366 ](https://doi.org/10.21873/anticanres.18366) Item in Clipboard # Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Akifumi Kuwano et al. Anticancer Res. 2026 Sep. Show details Display options Display options Format Abstract PubMed PMID Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) . 2026 Sep;46(9):5217-5227. doi: 10.21873/anticanres.18366. ### Authors [Akifumi Kuwano](https://pubmed.ncbi.nlm.nih.gov/?term=Kuwano+A&cauthor_id=42674706)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-1 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com."), [Masayoshi Yada](https://pubmed.ncbi.nlm.nih.gov/?term=Yada+M&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-3 "Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan."), [Kosuke Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Taikan Hamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Hamamoto+T&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Ryotaro Tanaka](https://pubmed.ncbi.nlm.nih.gov/?term=Tanaka+R&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Kazuki Kurosaka](https://pubmed.ncbi.nlm.nih.gov/?term=Kurosaka+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Hideo Suzuki](https://pubmed.ncbi.nlm.nih.gov/?term=Suzuki+H&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan."), [Kenta Motomura](https://pubmed.ncbi.nlm.nih.gov/?term=Motomura+K&cauthor_id=42674706)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674706/#short-view-affiliation-2 "Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.") ### Affiliations * 1 Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. * 2 Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan. * 3 Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan. * PMID: **42674706** * DOI: [ 10.21873/anticanres.18366 ](https://doi.org/10.21873/anticanres.18366) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background/aim:** Immune checkpoint inhibitor-based combination therapies are standard treatment options for unresectable hepatocellular carcinoma (HCC). However, conventional endpoints such as objective response rate, progression-free survival, and overall survival may not fully capture response dynamics, including depth of response (DpR), time to response, and duration of response. This study descriptively evaluated response dynamics in patients with unresectable HCC treated with durvalumab plus tremelimumab or atezolizumab plus bevacizumab. **Patients and methods:** This retrospective single-center study included 148 patients with unresectable HCC who received durvalumab-tremelimumab (n=53) or atezolizumab-bevacizumab (n=95). A reduction of ≥50% in target lesion diameter was defined as DpR50. Because of baseline imbalances and differences in observation period, the analysis was only descriptive and hypothesis-generating. **Results:** Fifty-three patients received durvalumab-tremelimumab and 95 received atezolizumab-bevacizumab. The overall response rate was 35.8% for the durvalumab-tremelimumab group and 27.4% for the atezolizumab-bevacizumab group, whereas the disease control rates were 54.7% and 71.6%, respectively. DpR50 was observed in 26.4% and 11.6% of patients, respectively. The median times to response were 2.3 and 3.3 months, and the median durations of response were 22.3 and 10.0 months, respectively. Durable response lasting ≥6 months occurred in 24.5% and 15.8% of all treated patients, respectively. The median PFS was 5.2 and 7.0 months, and median OS was 17.0 and 22.0 months, respectively. **Conclusion:** Therapy with durvalumab-tremelimumab was associated with deeper and more durable tumor shrinkage in selected responders, whereas atezolizumab-bevacizumab provided broader disease control mainly through stable disease. These findings should be interpreted as hypothesis-generating. **Keywords:** Hepatocellular carcinoma; atezolizumab plus bevacizumab; depth of response; durable response; durvalumab plus tremelimumab; tumor shrinkage. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Aged, 80 and over Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%2C+80+and+over%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged%2C+80+and+over) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antibodies, Monoclonal* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antibodies, Monoclonal* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antibodies, Monoclonal, Humanized* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Humanized) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antibodies, Monoclonal, Humanized* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Humanized) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antineoplastic Combined Chemotherapy Protocols* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Antineoplastic Combined Chemotherapy Protocols* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Bevacizumab* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bevacizumab%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bevacizumab) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Bevacizumab* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bevacizumab%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bevacizumab) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Carcinoma, Hepatocellular* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Hepatocellular%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Hepatocellular) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Carcinoma, Hepatocellular* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Hepatocellular%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Hepatocellular) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Carcinoma, Hepatocellular* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Hepatocellular%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Hepatocellular) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Liver Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Liver+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Liver Neoplasms* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver+Neoplasms%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Liver+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674706/) * Liver Neoplasms* / pathology Actions * [ Search in PubMed ](ht
## Related Clinical Research

- [Ambient light during sample processing causes verteporfin-driven protein cross-linking](https://medichelpline.com/clinical-feed/plos-one-17-ambient-light-drives-verteporfin-induced-protein-cross-linking-during-standard.md)
- [Site-Specific ApoA‑I Glycation Impairs HDL Function and May Promote Atherosclerosis in Diabetes](https://medichelpline.com/clinical-feed/pubmed-42639673.md) (DOI: 10.1161/CIRCULATIONAHA.125.078171)
- [GRK2 phosphorylation of AdipoR1 Ser205 drives diabetic cardiomyopathy; S205A mutation restores adi](https://medichelpline.com/clinical-feed/pubmed-42763212.md) (DOI: 10.3760/cma.j.cn112137-20260508-01227)
- [FDA Revises Nonclinical Testing Rules to Advance Alternatives to Animal Studies](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing.md)
- [3-Hydroxypropanamidines: From Antiplasmodial Leads to a Novel Antibacterial Scaffold](https://medichelpline.com/clinical-feed/biorxiv-15-3-hydroxypropanamidines-from-antiplasmodial-leads-to-a-novel-antibacterial.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.